Molecure SA
WSE:MOC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Taaleri Oyj
OMXH:TAALA
|
FI |
|
Bunzl plc
LSE:BNZL
|
UK |
|
G
|
Goyal Associates Ltd
BSE:530663
|
IN |
|
S.F. Holding Co Ltd
SZSE:002352
|
CN |
|
Sihui Fuji Electronics Technology Co Ltd
SZSE:300852
|
CN |
|
S
|
Shenzhen KTC Technology Co Ltd
SZSE:001308
|
CN |
Molecure SA
Total Current Liabilities
Molecure SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Molecure SA
WSE:MOC
|
Total Current Liabilities
zł3.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
C
|
Celon Pharma SA
WSE:CLN
|
Total Current Liabilities
zł54.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cannabis Poland SA
WSE:CBD
|
Total Current Liabilities
zł1.5m
|
CAGR 3-Years
63%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
Molecure SA
Glance View
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
See Also
What is Molecure SA's Total Current Liabilities?
Total Current Liabilities
3.6m
PLN
Based on the financial report for Dec 31, 2025, Molecure SA's Total Current Liabilities amounts to 3.6m PLN.
What is Molecure SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
-11%
Over the last year, the Total Current Liabilities growth was -30%. The average annual Total Current Liabilities growth rates for Molecure SA have been -20% over the past three years , -11% over the past five years .
